George SH, Greenaway J, Milea A, Clary V, Shaw S, Sharma M, Virtanen C, Shaw PA: Identification of abrogated pathways in fallopian tube epithelium from BRCA1 mutation carriers. J Pathol 2011, 225:106-17.

Kurman RJ, Shih Ie M: Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer–shifting the paradigm. Hum Pathol 2011, 42:918-31.

Kurman RJ, Vang R, Junge J, Hannibal CG, Kjaer SK, Shih Ie M: Papillary tubal hyperplasia: the putative precursor of ovarian atypical proliferative (borderline) serous tumors, noninvasive implants, and endosalpingiosis. Am J Surg Pathol 2011, 35:1605-14.

Visvanathan K, Vang R, Shaw P, Gross A, Soslow R, Parkash V, Shih Ie M, Kurman RJ: Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: a reproducibility study. Am J Surg Pathol 2011, 35:1766-75.

Kuhn E, Kurman RJ, Sehdev AS, Shih IM: Ki-67 labeling index as an adjunct in the diagnosis of serous tubal intraepithelial carcinoma. Int J Gyn Pathol 2012, 31:416-22.

Kuhn E, Kurman RJ, Shih IM: Ovarian cancer is an imported disease: fact or fiction? Curr Obstet Gynecol Rep 2012, 1:1-9.

Kuhn E, Kurman RJ, Soslow RA, Han G, Sehdev AS, Morin PJ, Wang TL, Shih IM: The diagnostic and biological implications of laminin expression in serous tubal intraepithelial carcinoma. Am J Surg Pathol 2012, 36:1826-34.

Kuhn E, Kurman RJ, Vang R, Sehdev AS, Han G, Soslow R, Wang TL, Shih IM: TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma- evidence supporting the clonal relationship of the two lesions. J Pathol 2012, 226:421-6.

Vang R, Visvanathan K, Gross A, Maambo E, Gupta M, Kuhn E, Li RF, Ronnett BM, Seidman JD, Yemelyanova A, Shih Ie M, Shaw PA, Soslow RA, Kurman RJ: Validation of an algorithm for the diagnosis of serous tubal intraepithelial carcinoma. Int J Gyn Pathol 2012, 31:243-53.

Tone AA, Virtanen C, Shaw P, Brown TJ: Prolonged postovulatory proinflammatory signaling in the fallopian tube epithelium may be mediated through a BRCA1/DAB2 axis. Clin Cancer Res 2012, 18:4334-44.

George SH, Milea A, Shaw P: Proliferation in the normal FTE is a hallmark of the follicular phase, not BRCA mutation status. Clin Cancer Res 2012, 18:6199-207.

Tian Y, Chen L, Zhang B, Zhang Z, Yu G, Clarke R, Xuan J, Shih IM, Wang Y: Genomic and network analysis to study the origin of ovarian cancer. Systems Biomedicine 2013, 1:55-64.

Kuhn E, Ayhan A, Shih Ie M, Seidman JD, Kurman RJ: Ovarian Brenner tumour: a morphologic and immunohistochemical analysis suggesting an origin from fallopian tube epithelium. Eur J Cancer 2013, 49:3839-49.

Vang R, Shih Ie M, Kurman RJ: Fallopian tube precursors of ovarian low- and high-grade serous neoplasms. Histopathology 2013, 62:44-58.

Nik NN, Vang R, Shih Ie M, Kurman RJ: Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma. Ann Rev Pathol 2014, 9:27-45.

Ardighieri L, Lonardi S, Moratto D, Facchetti F, Shih IM, Vermi W, Kurman RJ: Characterization of the immune cell repertoire in the normal fallopian tube. Int J Gyn Pathol 2014, 33:581-91.

Chui MH, Wang Y, Wu RC, Seidman J, Kurman RJ, Wang TL, Shih IM: Loss of ALDH1A1 expression is an early event in the pathogenesis of ovarian high-grade serous carcinoma. Mod Pathol 2015, 28:437-45.

Sherman-Baust CA, Kuhn E, Valle BL, Shih Ie M, Kurman RJ, Wang TL, Amano T, Ko MS, Miyoshi I, Araki Y, Lehrmann E, Zhang Y, Becker KG, Morin PJ: A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development. J Pathol 2014, 233:228-37.

George SH, Shaw P: BRCA and Early Events in the Development of Serous Ovarian Cancer. Frontiers Onc 2014, 4:5.

Zeppernick F, Meinhold-Heerlein I, Shih Ie M: Precursors of ovarian cancer in the fallopian tube: serous tubal intraepithelial carcinoma–an update. J Ob Gyn Res 2015, 41:6-11.

Morrison JC, Blanco LZ Jr, Vang R, Ronnett BM: Incidental serous tubal intraepithelial carcinoma and early invasive serous carcinoma in the nonprophylactic setting: analysis of a case series. Am J Surg Pathol 2015, 39:442-53.

Yu Y, Gaillard S, Phillip JM, Huang TC, Pinto SM, Tessarollo NG, Zhang Z, Pandey A, Wirtz D, Ayhan A, Davidson B, Wang TL, Shih IM: Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules. Cancer Cell 2015, 28:82-96.

Kobayashi Y, Kashima H, Wu RC, Jung JG, Kuan JC, Gu J, Xuan J, Sokoll L, Visvanathan K, Shih IM, Wang TL: Mevalonate Pathway Antagonist Inhibits Proliferation of Serous Tubal Intraepithelial Carcinoma and Ovarian Carcinoma in Mouse Models. Clin Cancer Res 2015, 21:4625-62.

Lheureux S, Shaw PA, Karakasis K, Oza AM: Cancer precursor lesions in the BRCA population at the time of prophylactic salpingo-oophorectomy: Accuracy of assessment and potential surrogate marker for prevention. Gyn Oncol 2015, 138:235-7.

George SH, Milea A, Sowamber R, Chehade R, Tone A, Shaw PA: Loss of LKB1 and p53 synergizes to alter fallopian tube epithelial phenotype and high-grade serous tumorigenesis. Oncogene 2015, Epub.

Kashima H, Wu RC, Wang Y, Sinno AK, Miyamoto T, Shiozawa T, Wang TL, Fader AN, Shih IeM. Laminin C1 expression by uterine carcinoma cells is associated with tumor progression. Gynecol Oncol. 2015 Nov;139(2):338-44.

Vang R, Levine DA, Soslow RA, Zaloudek C, Shih IeM, Kurman RJ. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study. Int J Gynecol Pathol. 2016 Jan;35(1):48-55.

Suryo Rahmanto Y, Jung JG, Wu RC, Kobayashi Y, Heaphy CM, Meeker AK, Wang TL, Shih IeM. Inactivating ARID1A Tumor Suppressor Enhances TERT Transcription and Maintains Telomere Length in Cancer Cells. J Biol Chem. 2016 Apr 29;291(18):9690-9.

Kurman RJ, Shih IeM. The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded. Am J Pathol. 2016 Apr ;186(4):733-47.

Sherman ME, Drapkin RI, Horowitz NS, Crum CP, Friedman S, Kwon JS, Levine DA, Shih IeM, Shoupe D, Swisher EM, Walker J, Trabert B, Greene MH, Samimi G, Temkin SM, Minasian LM. Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence. Cancer Prev Res (Phila). 2016 Sep;9(9):713-20.

Kuhn E, Wang TL, Doberstein K, Bahadirli-Talbott A, Ayhan A, Sehdev AS, Drapkin R, Kurman RJ, Shih IeM. CCNE1 amplification and centrosome number abnormality in serous tubal intraepithelial carcinoma: further evidence supporting its role as a precursor of ovarian high-grade serous carcinoma. Mod Pathol. 2016 Oct;29(10):1254-61.

Jung JG, Shih IM, Park JT, Gerry E, Kim TH, Ayhan A, Handschuh K, Davidson B, Fader AN, Selleri L, Wang TL. Ovarian Cancer Chemoresistance Relies on the Stem Cell Reprogramming Factor PBX1. Cancer Res. 2016 Nov 1;76(21):6351-6361.